KV1.3 blockers, which are generally well tolerated, and do not affect the ability of rodents to clear infections or of rhesus macaques to develop protective vaccine responses (Beeton et al., 2006; Pereira et al., 2007), therefore constitute attractive therapeutic candidates for immunocytoprotection in ischemic stroke. Here, KCNA3 is linked to infection.